BCDA - AUR MRSN and BCDA among pre market gainers
BioCardia (NASDAQ:BCDA) +32% receives FDA breakthrough device designation for CardiAMP cell therapy system for heart failure. Bon Natural Life (NASDAQ:BON) +29% on FY results. Lightning eMotors (NYSE:ZEV) +19% after electrification deal with General Motors. Redwire (NYSE:RDW) +11% cheers FY21 revenue estimates, uncontracted backlog. Ralph Lauren (NYSE:RL) +9% on FQ3 results. Regis (NYSE:RGS) +8% on FQ2 results. T-Mobile (NASDAQ:TMUS) +8% on Q4 results. JX Luxventure (NASDAQ:LLL) +8%. Biophytis (NASDAQ:BPTS) +7% to treat severe COVID-19 patients with Sarconeos in Brazil under EAP. HeartBeam (NASDAQ:BEAT) +6% on LIVMOR team up for cloud-based remote monitoring portal. Flex (NASDAQ:FLEX) +6% to sell $500M of convertible preferred equity in Nextracker to TPG Rise Climate. Pasithea Therapeutics (NASDAQ:KTTA) +6% initiates new chemical entity drug development program in multiple sclerosis. Aurora Innovation (NASDAQ:AUR) +5%. Mersana Therapeutics (NASDAQ:MRSN) +5% announces research collaboration and license agreement with Janssen to advance novel antibody-drug conjugates.
For further details see:
AUR, MRSN and BCDA among pre market gainers